Trade names Bridion
Clinical data
Uses Reversal of neuromuscular blockade from rocuronium and vecuronium
Contraindications Renal impairment
Routes of administration Intravenous
Dosage Based upon response to train-of-four stimulation:
  • 2+ twitches: 2 mg/kg
  • 1-2 posttetanic twitches: 4 mg/kg
Reversal immediately after administration of rocuronium 1.2 mg/kg: 16 mg/kg
Mechanism of action Encapsulation of rocuronium or vecuronium
Adverse effects Bradycardia, may interfere with hormonal contraceptives
Physical and chemical data
Formula C72H112O48S8
Molar mass 2002.12 g/mol

Sugammadex is used to reverse neuromuscular blockade from rocuronium and vecuronium.


If a patient requires reparaylsis after administration of sugammadex (up to 4 mg/kg), rocuronium or vecuronium can be re-administered after a minimum waiting time.[1]

Drug and dose to be administered Minimum waiting time
Rocuronium 1.2 mg/kg 5 minutes
Rocuronium 0.6 mg/kg or

vecuronium 0.1 mg/kg

4 hours


Absolute contraindications

  • Previous anaphylactic reaction to sugammadex


  • Sugammadex can also bind steroid-structured molecules such as estrogen and tamoxifen. Consideration to using other agents to reverse NMB should be given to those patients on tamoxifen or toremifene for breast cancer. Female patients of child-bearing age on oral birth control should be advised of the potential of a short-term decrease in the efficacy of this method of birth control following reversal with sugammadex.
  • Renal disease is a relative contraindication to the use of sugammadex as it is mainly renally cleared. With decreased renal clearance, the drug will stay in the body longer and the safety profile of this kind of drug exposure has not been well studied.



Mechanism of action

Adverse effects


Chemistry and formulation



  1. "BRIDION® (sugammadex) Injection Drug Label (FDA)" (PDF).